Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
Mainz Biomed (NASDAQ:MYNZ) has announced a strategic collaboration with CARE diagnostica Laborreagenzien GmbH to expand colorectal cancer screening services in Germany. The partnership will integrate Mainz Biomed's ColoAlert® test into CARE's existing screening programs, which currently serve more than 15 statutory health insurance companies.
The collaboration enables CARE to enhance its screening offerings by incorporating ColoAlert®'s molecular genetic analysis capabilities, which use PCR to analyze biomarkers in stool samples. This advanced technology aims to improve early-stage detection rates compared to traditional fecal immunochemical tests (FIT).
Mainz Biomed (NASDAQ:MYNZ) ha annunciato una collaborazione strategica con CARE diagnostica Laborreagenzien GmbH per ampliare i servizi di screening del cancro colorettale in Germania. La partnership integrerà il test ColoAlert® di Mainz Biomed nei programmi di screening già attivi di CARE, che attualmente coinvolgono più di 15 compagnie di assicurazione sanitaria obbligatoria.
Questa collaborazione permette a CARE di migliorare le proprie offerte di screening includendo le capacità di analisi genetica molecolare di ColoAlert®, che utilizza la PCR per analizzare biomarcatori nelle feci. Questa tecnologia avanzata mira a incrementare i tassi di rilevamento precoce rispetto ai tradizionali test immunochimici fecali (FIT).
Mainz Biomed (NASDAQ:MYNZ) ha anunciado una colaboración estratégica con CARE diagnostica Laborreagenzien GmbH para ampliar los servicios de detección de cáncer colorrectal en Alemania. La asociación integrará la prueba ColoAlert® de Mainz Biomed en los programas de detección existentes de CARE, que actualmente atienden a más de 15 compañías de seguro de salud estatutario.
La colaboración permite a CARE mejorar sus servicios de detección incorporando las capacidades de análisis genético molecular de ColoAlert®, que utiliza PCR para analizar biomarcadores en muestras de heces. Esta tecnología avanzada busca mejorar las tasas de detección en etapas tempranas en comparación con las pruebas inmunoquímicas fecales tradicionales (FIT).
Mainz Biomed (NASDAQ:MYNZ)는 독일에서 대장암 검진 서비스를 확대하기 위해 CARE diagnostica Laborreagenzien GmbH와 전략적 협력을 발표했습니다. 이번 파트너십은 Mainz Biomed의 ColoAlert® 검사를 CARE의 기존 검진 프로그램에 통합할 예정이며, CARE는 현재 15개 이상의 법정 건강보험사를 대상으로 서비스를 제공하고 있습니다.
이번 협력을 통해 CARE는 PCR을 이용해 대변 샘플 내 바이오마커를 분석하는 ColoAlert®의 분자 유전학 분석 기능을 도입하여 검진 서비스를 강화할 수 있게 되었습니다. 이 첨단 기술은 기존의 분변 면역화학 검사(FIT)보다 조기 발견률을 향상시키는 것을 목표로 합니다.
Mainz Biomed (NASDAQ:MYNZ) a annoncé une collaboration stratégique avec CARE diagnostica Laborreagenzien GmbH pour étendre les services de dépistage du cancer colorectal en Allemagne. Ce partenariat intégrera le test ColoAlert® de Mainz Biomed dans les programmes de dépistage existants de CARE, qui desservent actuellement plus de 15 caisses d'assurance maladie légales.
Cette collaboration permet à CARE d'améliorer ses offres de dépistage en incorporant les capacités d'analyse génétique moléculaire de ColoAlert®, qui utilise la PCR pour analyser les biomarqueurs dans les échantillons de selles. Cette technologie avancée vise à améliorer les taux de détection précoce par rapport aux tests immunochimiques fécaux traditionnels (FIT).
Mainz Biomed (NASDAQ:MYNZ) hat eine strategische Zusammenarbeit mit CARE diagnostica Laborreagenzien GmbH angekündigt, um die Darmkrebsvorsorge in Deutschland auszubauen. Die Partnerschaft wird den ColoAlert®-Test von Mainz Biomed in die bestehenden Vorsorgeprogramme von CARE integrieren, die derzeit mehr als 15 gesetzliche Krankenkassen betreuen.
Durch die Zusammenarbeit kann CARE sein Vorsorgeangebot erweitern, indem die molekulargenetischen Analysefähigkeiten von ColoAlert®, die mittels PCR Biomarker in Stuhlproben analysieren, integriert werden. Diese fortschrittliche Technologie zielt darauf ab, die Früherkennungsraten im Vergleich zu herkömmlichen immunchemischen Stuhltests (FIT) zu verbessern.
- Partnership with CARE provides access to 15+ German health insurance companies
- Immediate implementation of the collaboration agreement
- Expansion of ColoAlert® distribution in the German market
- Enhanced detection capabilities through molecular genetic analysis
- None.
CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening
BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a diagnostics company specializing in the early detection of cancer, today announced a collaboration with CARE diagnostica Laborreagenzien GmbH (“CARE”).
CARE is currently working with more than 15 statutory health insurance companies as part of special online-based screening concepts based on the widely used fecal immuniochemical test (FIT). Thanks to the cooperation with Mainz Biomed, the range of services for risk groups can now be expanded to include the ColoAlert® test, which uses molecular genetic analysis of biomarkers in stool using PCR to increase the detection rate, particularly in the early stages of the disease.
The cooperation comes into effect immediately and supports Mainz Biomed in further expanding the distribution of ColoAlert® in the German market. It is in line with the growing demand for personalized screening solutions that focus on early intervention.
Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
About CARE diagnostica Laborreagenzien GmbH
CARE diagnostica Laborreagenzien GmbH stands for quality and pioneering decisions in the field of colorectal cancer screening in Germany for over 40 years. Further information can be found under carediag.de.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What is the new partnership between Mainz Biomed (MYNZ) and CARE diagnostica?
How many health insurance companies will have access to Mainz Biomed's ColoAlert test?
What advantages does ColoAlert offer over traditional FIT tests?
When does the Mainz Biomed and CARE partnership take effect?
How will this partnership affect Mainz Biomed's market presence in Germany?
